ES2055038T3 - Porfirinas y medicamentos para el tratamiento del cancer. - Google Patents

Porfirinas y medicamentos para el tratamiento del cancer.

Info

Publication number
ES2055038T3
ES2055038T3 ES89301924T ES89301924T ES2055038T3 ES 2055038 T3 ES2055038 T3 ES 2055038T3 ES 89301924 T ES89301924 T ES 89301924T ES 89301924 T ES89301924 T ES 89301924T ES 2055038 T3 ES2055038 T3 ES 2055038T3
Authority
ES
Spain
Prior art keywords
porphyrins
different
medicines
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89301924T
Other languages
English (en)
Inventor
Raymond Bonnett
Morris Cyril Berenbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scotia Holdings PLC
Original Assignee
Scotia Holdings PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings PLC filed Critical Scotia Holdings PLC
Application granted granted Critical
Publication of ES2055038T3 publication Critical patent/ES2055038T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

ESTA INVENCION PROPORCIONA NUEVOS COMPUESTOS PARA TERAPIA DE TUMORES SUSCEPTIBLES DE NECROSIS, CUANDO SE ADMINISTRA UN COMPUESTO APROPIADO SEGUIDO POR ILUMINACION CON LUZ DE UNA LONGITUD DE ONDA ABSORBIDA POR EL COMPUESTO. LOS COMPUESTOS SON DIHIDRO - PORFIRINAS DE FORMULA (I), O LAS CORRESPONDIENTES TETRAHIDROPORFIRINAS, TENIENDO N UN VALOR DE 1 A 3 Y CADA UNO DE LOS SUSTITUYENTES R QUE PUEDEN SER IGUALES O DIFERENTES Y ESTAR EN LA MISMA O DIFERENTE POSICION EN SU CORRESPONDIENTE ANILLO FENILO, ES UN GRUPO HIDROXI.
ES89301924T 1988-03-11 1989-02-27 Porfirinas y medicamentos para el tratamiento del cancer. Expired - Lifetime ES2055038T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888805849A GB8805849D0 (en) 1988-03-11 1988-03-11 Porphyrins & cancer treatment

Publications (1)

Publication Number Publication Date
ES2055038T3 true ES2055038T3 (es) 1994-08-16

Family

ID=10633278

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89301924T Expired - Lifetime ES2055038T3 (es) 1988-03-11 1989-02-27 Porfirinas y medicamentos para el tratamiento del cancer.

Country Status (17)

Country Link
US (1) US4992257A (es)
EP (1) EP0337601B1 (es)
JP (1) JP2785033B2 (es)
KR (1) KR970011392B1 (es)
AT (1) ATE89002T1 (es)
AU (1) AU611774C (es)
BR (1) BR1100662A (es)
CA (1) CA1338737C (es)
DE (2) DE10299012I2 (es)
ES (1) ES2055038T3 (es)
GB (1) GB8805849D0 (es)
HK (1) HK129693A (es)
IE (1) IE63290B1 (es)
LU (1) LU90907I2 (es)
NL (1) NL300089I2 (es)
NZ (1) NZ228225A (es)
ZA (1) ZA891653B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162519A (en) * 1988-03-11 1992-11-10 Efamol Holdings Plc Porphyrins and cancer treatment
US5219878A (en) * 1990-10-05 1993-06-15 Queen's University Tetrapyrrole hydroxyalkylamide photochemotherapeutic agents
US5262532A (en) * 1991-07-22 1993-11-16 E.R. Squibb & Sons, Inc. Paramagnetic metalloporphyrins as contrast agents for magnetic resonance imaging
US6362175B1 (en) 1991-09-20 2002-03-26 The Trustees Of The University Of Pennsylvania Porphyrin compounds for imaging tissue oxygen
PL165249B1 (pl) * 1991-10-29 1994-11-30 Wojskowa Akad Tech Sposób otrzymywania soli kompleksowych hematoporfiryny i jej pochodnych PL PL PL PL PL PL PL
PL172480B1 (pl) * 1992-11-20 1997-09-30 Univ British Columbia Kompozycja do niszczenia lub uszkadzania obszaru nowego unaczynienia PL PL
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
JPH07233065A (ja) * 1993-12-27 1995-09-05 Canon Inc ピリリウム塩又はピリリウム類似塩を含む光化学治療薬
GB9408746D0 (en) * 1994-05-03 1994-06-22 Scotia Holdings Plc Tumour locallising photosensitising compounds
WO1996009053A1 (en) * 1994-09-20 1996-03-28 Duke University Oxidoreductase activity of manganic porphyrins
US6176842B1 (en) * 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
US6210356B1 (en) * 1998-08-05 2001-04-03 Ekos Corporation Ultrasound assembly for use with a catheter
JPH11509180A (ja) * 1995-06-07 1999-08-17 デューク・ユニバーシティ 酸化体脱除剤
US5877165A (en) * 1995-11-02 1999-03-02 Brookhaven Science Associates Boronated porhyrins and methods for their use
ATE230801T1 (de) 1996-10-03 2003-01-15 Canon Kk Verfahren zur detektion von zielnukleinsäure, verfahren zu ihrer quantifizierung und pyrylium- verbindungen zur chemilumineszenz-analyse
US6676626B1 (en) 1998-05-01 2004-01-13 Ekos Corporation Ultrasound assembly with increased efficacy
US6582392B1 (en) 1998-05-01 2003-06-24 Ekos Corporation Ultrasound assembly for use with a catheter
JP2001521939A (ja) 1997-11-03 2001-11-13 デューク・ユニバーシティー 置換されたポルフィリン類
DE19814405C2 (de) * 1998-03-31 2000-03-02 Schastak Astrid Porphyrine und ihre Verwendung als Photosensitizer
DE69928655T2 (de) 1998-04-24 2006-08-24 Duke University Substituierte porphyrine
AU765509B2 (en) * 1998-08-28 2003-09-18 Destiny Pharma Limited Porphyrin derivatives, their use in photodynamic therapy and medical devices containing them
EP1155019B1 (en) 1999-01-25 2005-12-07 National Jewish Medical and Research Center Substituted porphyrins and their therapeutic use
US6482943B1 (en) * 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
GB0001455D0 (en) 2000-01-21 2000-03-15 Scotia Holdings Plc Porphyrins and related compounds
JP2004520380A (ja) 2001-01-19 2004-07-08 ナショナル・ジュウィッシュ・メディカル・アンド・リサーチ・センター 癌治療本出願は、２００１年１月１９日に出願の仮出願番号第６０／２６２，３９０号の優先権を主張し、その全ての内容は、参照により本願明細書に援用したものとする。
JP2005508864A (ja) 2001-06-01 2005-04-07 ナショナル・ジュウィッシュ・メディカル・アンド・リサーチ・センター 糖尿病の治療、または移植術における使用、または免疫寛容の誘導のためのオキシダントスカベンジャー
AU2002359576A1 (en) 2001-12-03 2003-06-17 Ekos Corporation Catheter with multiple ultrasound radiating members
PT102721B (pt) * 2002-02-01 2011-01-24 Cipan Companhia Industr Prod De Antibioticos S A Compostos macrocíclicos tetrapirrólicos com rendimento quântico de oxigénio singuleto adequado à terapia fotodinâmica e processos para a sua preparação
US8226629B1 (en) 2002-04-01 2012-07-24 Ekos Corporation Ultrasonic catheter power control
EP1513537A4 (en) 2002-06-07 2006-09-06 Univ Duke Substituted porphyrins
US6921371B2 (en) * 2002-10-14 2005-07-26 Ekos Corporation Ultrasound radiating members for catheter
ITFI20020200A1 (it) * 2002-10-21 2004-04-22 Molteni & C Dei Flii Alitti S P A Societa L Porfirine meso-sostituite.
CA2437638A1 (en) 2003-08-20 2005-02-20 John Robert North Photodynamic therapy
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy
CA2457214A1 (en) 2004-02-06 2005-08-06 Qlt Inc. Photodynamic therapy for the treatment of acne
MX2007000338A (es) 2004-06-09 2007-03-28 Quadra Logic Tech Inc Terapia fotodinamica para el tratamiento de trastornos hiperactivos de glandulas sebaceas.
US7825153B2 (en) * 2004-08-16 2010-11-02 Ceramoptec Industries, Inc. Photosensitizer formulations and their use
DE102005015286A1 (de) * 2005-04-04 2006-10-05 Tetrapdt Gmbh Photosensibilisatoren als Arzneimittelträger für lokale Markierung und Therapie von neoplastischem Gewebe
US10182833B2 (en) 2007-01-08 2019-01-22 Ekos Corporation Power parameters for ultrasonic catheter
WO2009002881A1 (en) 2007-06-22 2008-12-31 Ekos Corporation Method and apparatus for treatment of intracranial hemorrhages
US20090036952A1 (en) 2007-07-30 2009-02-05 National Yang-Ming University Induction driven light module and use thereof
US20090187137A1 (en) * 2007-12-14 2009-07-23 Kim Volz Ultrasound pulse shaping
US11382895B2 (en) 2008-05-23 2022-07-12 National Jewish Health Methods for treating injury associated with exposure to an alkylating species
PT3459955T (pt) 2008-09-18 2022-11-29 Biolitec Unternehmensberatungs Ii Ag Método e aplicação inovadores de porfirinas e cloros não simetricamente meso-substituídos para pdt
US9211283B2 (en) 2009-12-11 2015-12-15 Biolitec Pharma Marketing Ltd Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
US20130289089A1 (en) 2011-01-13 2013-10-31 Jerome A. Morris Pharmaceutical Compositions for Topical Delivery of Photosensitizers and Uses Thereof
KR20150030763A (ko) 2012-07-11 2015-03-20 더미라, 인코포레이티드 감광제의 국부 전달을 위한 약제학적 조성물 및 이의 이용
US9550072B2 (en) 2012-08-03 2017-01-24 Cerca Solutions, LLC Diagnostic device, therapeutic device, and uses thereof
EP3201201B1 (en) 2014-09-30 2022-01-26 biolitec unternehmensbeteiligungs II AG Specifically meso-substituted porphyrins and chlorins for photodynamic therapy
EP3307388B1 (en) 2015-06-10 2022-06-22 Ekos Corporation Ultrasound catheter
EP3894421A1 (en) 2018-12-10 2021-10-20 Universität Hamburg Specifically glyco-substituted porphyrins and chlorins for photodynamic therapy
EP4225759A1 (en) 2020-10-05 2023-08-16 biolitec Unternehmensbeteiligungs II AG Tetrapyrrole-based compounds and their formulations for anti-microbial therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2740794A (en) * 1954-07-26 1956-04-03 Exxon Research Engineering Co Synthesis of novel vanadium porphyrin
US3076813A (en) * 1957-11-13 1963-02-05 Monsanto Chemicals alpha, beta, gamma, sigma-tetra-arylporphins
US3687863A (en) * 1970-05-25 1972-08-29 Gen Telephone & Elect Optical filters containing tetraphenyl-porphins and method of making same
DE2308252A1 (de) * 1973-02-20 1974-08-22 Basf Ag Verfahren zur herstellung von mesotetraarylporphinen
US4330637A (en) * 1981-01-05 1982-05-18 Western Electric Company, Inc. Encapsulated electronic devices and encapsulating compositions
EP0127797B1 (de) * 1983-06-03 1987-06-16 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Markermoleküle für Fluoreszenz-Immuno-Assays sowie Verfahren und Zwischenprodukte zu deren Herstellung
GB8429845D0 (en) * 1984-11-26 1985-01-03 Efamol Ltd Porphyrins & cancer treatment
GB8522670D0 (en) * 1985-09-13 1985-10-16 Efamol Ltd Drug treatments

Also Published As

Publication number Publication date
NL300089I1 (nl) 2002-07-01
DE10299012I1 (de) 2002-07-18
DE68906301T2 (de) 1993-09-30
NZ228225A (en) 1990-08-28
ZA891653B (en) 1989-11-29
AU3097589A (en) 1989-09-14
US4992257A (en) 1991-02-12
AU611774B2 (en) 1991-06-20
JPH01275528A (ja) 1989-11-06
EP0337601A1 (en) 1989-10-18
EP0337601B1 (en) 1993-05-05
LU90907I2 (fr) 2003-04-30
GB8805849D0 (en) 1988-04-13
BR1100662A (pt) 1999-10-13
NL300089I2 (nl) 2002-08-01
DE68906301D1 (de) 1993-06-09
IE63290B1 (en) 1995-04-05
JP2785033B2 (ja) 1998-08-13
AU611774C (en) 2002-02-21
DE10299012I2 (de) 2004-05-06
ATE89002T1 (de) 1993-05-15
CA1338737C (en) 1996-11-26
KR970011392B1 (ko) 1997-07-10
IE890687L (en) 1989-09-11
HK129693A (en) 1993-12-03
KR890014548A (ko) 1989-10-24

Similar Documents

Publication Publication Date Title
ES2074867T3 (es) Derivados de quinazolina para potenciar la actividad antitumoral.
DE68910767D1 (de) Anordnung von lichtemittierenden Dioden.
DE3885300D1 (de) Heilen von wunden.
ES2040838T3 (es) Compuestos piperazinil-heterociclicos.
ES2055735T3 (es) Agentes citotoxicos con longitud de onda especifica.
DE3774918D1 (de) Cancerostatisches mittel.
EP0933995A4 (en) METHOD OF TREATING ENDOTHELIAL LESIONS
ES2014523A6 (es) Procedimiento de preparar derivados de aril-heteroarilcarbinoles.
ES2129485T3 (es) Derivados de acidos guanidinoalquil-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.
EA200300544A1 (ru) Эффективные противоопухолевые лекарственные средства
IT8848491A0 (it) Impiego in terapeutica di derivati del 4h-benzo-4,5-cicloepta-1,2-bqti ofene
DE69202441D1 (de) Melatoninderivate und Kombinationen mit Antiestrogenen zur Behandlung von Brustkarzinoma.
KR900700495A (ko) 치료제로서 유용한 치환된 아데닌 유도체
DE69130586D1 (de) Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
ES2092981T3 (es) Derivados de aristeromicina/adenosina.
ES8700232A1 (es) Un procedimiento para producir 1a,25-dihidroxi-26,27-dime- tilcolecalciferol
ES2179204T3 (es) Hidrazinas 2-aminocarbonil-1,2-bis(metilsulfonil)-1-sustituidas antitumorales.
FR2523986B1 (fr) Articles medicaux sterilisables par irradiation
ES2064328T3 (es) Indolilpropanoles, procedimiento para su fabricacion y su uso, asi como preparaciones que contienen los compuestos.
MX9203405A (es) Compuestos activos para usarse en el tratamiento de tumores.
FI881879A7 (fi) Valonsäteiden säteilyttämislaite lääketieteelliseen käyttöön.
ES2113345T3 (es) Tratamiento de la disfuncion cardiaca con la ayuda de compuestos 15-ceto-prostaglandina.
ES2042726T3 (es) Beta-alquilmelatoninas.
UY24009A1 (es) Compuestos ariltio útiles como agentes antivirales y antibacteriales
ES2081834T3 (es) Pirrolidin-2-onas 4-metil y 4-etil sustituidas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 337601

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: TEMOPORFINA (FOSCAN)

Spc suppl protection certif: C200200010

Filing date: 20020424

SPCG Supplementary protection certificate granted

Free format text: TEMOPORFINA (FOSCAN).

Spc suppl protection certif: C200200010

Filing date: 20020424

Expiry date: 20140227

Effective date: 20040614